EA201691075A1 - Способы оксимной конъюгации с кетон-модифицированными полипептидами - Google Patents
Способы оксимной конъюгации с кетон-модифицированными полипептидамиInfo
- Publication number
- EA201691075A1 EA201691075A1 EA201691075A EA201691075A EA201691075A1 EA 201691075 A1 EA201691075 A1 EA 201691075A1 EA 201691075 A EA201691075 A EA 201691075A EA 201691075 A EA201691075 A EA 201691075A EA 201691075 A1 EA201691075 A1 EA 201691075A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protein
- ketone
- oxime
- payload
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000021615 conjugation Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 235000018102 proteins Nutrition 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 abstract 3
- 150000002576 ketones Chemical class 0.000 abstract 3
- 150000002923 oximes Chemical class 0.000 abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 230000001268 conjugating effect Effects 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909236P | 2013-11-26 | 2013-11-26 | |
| US201462002614P | 2014-05-23 | 2014-05-23 | |
| PCT/IB2014/066300 WO2015079376A1 (en) | 2013-11-26 | 2014-11-24 | Methods for oxime conjugation to ketone-modified polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201691075A1 true EA201691075A1 (ru) | 2016-09-30 |
Family
ID=52117931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691075A EA201691075A1 (ru) | 2013-11-26 | 2014-11-24 | Способы оксимной конъюгации с кетон-модифицированными полипептидами |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10172948B2 (https=) |
| EP (1) | EP3074048B1 (https=) |
| JP (1) | JP6609563B2 (https=) |
| KR (1) | KR20160088429A (https=) |
| CN (1) | CN105764530B (https=) |
| AU (1) | AU2014356126B2 (https=) |
| CA (1) | CA2928087A1 (https=) |
| EA (1) | EA201691075A1 (https=) |
| ES (1) | ES2729643T3 (https=) |
| IL (1) | IL245244A0 (https=) |
| MX (1) | MX2016006674A (https=) |
| TW (1) | TWI572361B (https=) |
| UY (1) | UY35854A (https=) |
| WO (1) | WO2015079376A1 (https=) |
| ZA (1) | ZA201602603B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2732574T3 (es) | 2012-11-30 | 2019-11-25 | Novartis Ag | Métodos para preparar conjugados a partir de proteínas que contienen disulfuro |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| KR102508023B1 (ko) | 2014-09-03 | 2023-03-10 | 이뮤노젠 아이엔씨 | 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트 |
| US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| WO2017051254A1 (en) * | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
| EP3355931B1 (en) | 2015-10-01 | 2024-06-26 | Novo Nordisk A/S | Protein conjugates |
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| AU2016359230B2 (en) | 2015-11-25 | 2020-04-23 | Ligachem Biosciences Inc. | Conjugates comprising self-immolative groups and methods related thereto |
| AU2016359235B2 (en) | 2015-11-25 | 2022-09-15 | Ligachem Biosciences Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| JP7002733B2 (ja) * | 2016-11-18 | 2022-02-04 | 国立大学法人 鹿児島大学 | ＩｇＧ結合ペプチドを含む固相担体及びＩｇＧの分離方法 |
| CA3058360A1 (en) | 2017-03-29 | 2018-10-04 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN112601555A (zh) | 2018-05-09 | 2021-04-02 | 乐高化学生物科学股份有限公司 | 与抗cd19抗体药物结合物相关的组合物和方法 |
| SG11202100721SA (en) | 2018-07-23 | 2021-02-25 | Univ Alberta | Genetically-encoded bicyclic peptide libraries |
| CA3120393A1 (en) * | 2018-11-28 | 2020-06-04 | The Governors Of The University Of Alberta | Genetically-encoded macrocyclic peptide libraries bearing a pharmacophore |
| KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239110B1 (en) | 1990-02-22 | 2001-05-29 | W.R. Grace & Co. -Conn. | Synthetic analogs of thrombospondin and therapeutic use thereof |
| WO1999013062A1 (en) | 1997-09-09 | 1999-03-18 | Nycomed Imaging As | Factors vii fragments and analogs thereof and their use in the treatment of blood clotting disorders |
| WO1999013063A1 (en) | 1997-09-09 | 1999-03-18 | Nycomed Imaging As | Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| US20090131306A1 (en) | 2007-06-15 | 2009-05-21 | Adherex Technologies, Inc. | Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor |
| US20110172126A1 (en) | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| JP6480340B2 (ja) | 2012-11-15 | 2019-03-06 | ブランデイズ ユニバーシティー | 環状ジスルフィドを用いるシステイン残基のテザリング |
| ES2732574T3 (es) * | 2012-11-30 | 2019-11-25 | Novartis Ag | Métodos para preparar conjugados a partir de proteínas que contienen disulfuro |
-
2014
- 2014-11-24 EA EA201691075A patent/EA201691075A1/ru unknown
- 2014-11-24 AU AU2014356126A patent/AU2014356126B2/en not_active Ceased
- 2014-11-24 JP JP2016554939A patent/JP6609563B2/ja not_active Expired - Fee Related
- 2014-11-24 WO PCT/IB2014/066300 patent/WO2015079376A1/en not_active Ceased
- 2014-11-24 CN CN201480064270.7A patent/CN105764530B/zh not_active Expired - Fee Related
- 2014-11-24 CA CA2928087A patent/CA2928087A1/en not_active Abandoned
- 2014-11-24 ES ES14815051T patent/ES2729643T3/es active Active
- 2014-11-24 MX MX2016006674A patent/MX2016006674A/es unknown
- 2014-11-24 KR KR1020167016645A patent/KR20160088429A/ko not_active Withdrawn
- 2014-11-24 US US14/551,187 patent/US10172948B2/en active Active
- 2014-11-24 EP EP14815051.9A patent/EP3074048B1/en not_active Not-in-force
- 2014-11-25 TW TW103140861A patent/TWI572361B/zh not_active IP Right Cessation
- 2014-11-25 UY UY0001035854A patent/UY35854A/es not_active Application Discontinuation
-
2016
- 2016-04-15 ZA ZA2016/02603A patent/ZA201602603B/en unknown
- 2016-04-20 IL IL245244A patent/IL245244A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2928087A1 (en) | 2015-06-04 |
| EP3074048A1 (en) | 2016-10-05 |
| MX2016006674A (es) | 2016-12-09 |
| TW201524520A (zh) | 2015-07-01 |
| US20150150998A1 (en) | 2015-06-04 |
| AU2014356126B2 (en) | 2017-01-05 |
| CN105764530B (zh) | 2019-09-13 |
| UY35854A (es) | 2015-06-30 |
| JP6609563B2 (ja) | 2019-11-20 |
| US10172948B2 (en) | 2019-01-08 |
| IL245244A0 (en) | 2016-06-30 |
| WO2015079376A1 (en) | 2015-06-04 |
| AU2014356126A1 (en) | 2016-05-19 |
| EP3074048B1 (en) | 2019-03-06 |
| JP2016539190A (ja) | 2016-12-15 |
| CN105764530A (zh) | 2016-07-13 |
| ZA201602603B (en) | 2017-06-28 |
| ES2729643T3 (es) | 2019-11-05 |
| KR20160088429A (ko) | 2016-07-25 |
| TWI572361B (zh) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691075A1 (ru) | Способы оксимной конъюгации с кетон-модифицированными полипептидами | |
| MX2015006868A (es) | Metodos para la elaboracion de conjugados a partir de proteinas que contienen disulfuro. | |
| CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
| CY1125141T1 (el) | Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d | |
| CY1123995T1 (el) | Αντισωματα ειδικα για υπερφωσφορυλιωμενη ταυ και μεθοδοι χρησης αυτων | |
| CY1123743T1 (el) | Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου | |
| CY1123525T1 (el) | Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων | |
| PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
| PH12018500062A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| HK1249048A1 (zh) | 靶向afp肽/mhc复合体的构建体及其用途 | |
| CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
| MX2015012059A (es) | Anticuerpos biespecificos tetravalentes. | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
| MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. | |
| EA201790438A1 (ru) | Антигенсвязывающие белки, которые связываются с cxcr5 | |
| MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| MX2017005199A (es) | Conjugados y reactivos de conjugacion. | |
| PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
| PH12016500403A1 (en) | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof | |
| EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
| MX2018001686A (es) | Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco. | |
| CY1122728T1 (el) | Αντισωματα εναντι hpa-1a | |
| EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 |